Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting

BACKGROUND: A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evidence suggests that DAT may be associated with an increased ischemic risk. This raises the qu...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Cardiol Heart Vasc
Auteurs principaux: Riesinger, Lisa, Strobl, Claudia, Leistner, David M., Gori, Tommaso, Akin, Ibrahim, Mehr, Michael, Kellnar, Antonia, Mahabadi, Amir A., Bogossian, Harilaos, Block, Michael, Edelmann, Frank, Sarafoff, Nikolaus, Sibbing, Dirk, Ince, Hüseyin, Rassaf, Tienush, Mansmann, Ulrich, Mehilli, Julinda, Kääb, Stefan, Hausleiter, Jörg, Massberg, Steffen, Wakili, Reza
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Original Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256176/
https://ncbi.nlm.nih.gov/pubmed/34258380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijcha.2021.100810
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires